$6.00
2.44% yesterday
Nasdaq, Jun 27, 10:00 pm CET
ISIN
CA74319B5027
Symbol
PROF

Profound Medical Corp Stock price

$6.00
+0.73 13.74% 1M
-1.15 16.08% 6M
-1.51 20.11% YTD
-2.88 32.43% 1Y
-1.39 18.81% 3Y
-10.08 62.69% 5Y
-4.19 41.09% 10Y
-4.19 41.09% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.15 2.44%
ISIN
CA74319B5027
Symbol
PROF
Sector

Key metrics

Basic
Market capitalization
$183.8m
Enterprise Value
$142.2m
Net debt
$-41.6m
Cash
$46.4m
Shares outstanding
30.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
15.50 | 10.05
EV/Sales
11.99 | 7.78
EV/FCF
negative
P/B
3.55
Financial Health
Equity Ratio
86.03%
Return on Equity
-46.04%
ROCE
-65.43%
ROIC
-285.10%
Debt/Equity
0.10
Financials (TTM | estimate)
Revenue
$11.9m | $18.3m
EBITDA
$-35.6m | $-38.6m
EBIT
$-36.4m
Net Income
$-32.0m | $-33.7m
Free Cash Flow
$-26.6m
Growth (TTM | estimate)
Revenue
63.59% | 71.17%
EBITDA
-26.59% | -20.00%
EBIT
-24.23%
Net Income
-14.02% | -21.10%
Free Cash Flow
-23.50%
Margin (TTM | estimate)
Gross
67.64%
EBITDA
-299.76% | -210.90%
EBIT
-306.45%
Net
-269.39% | -184.28%
Free Cash Flow
-224.57%
More
EPS
$-1.06
FCF per Share
$-0.89
Short interest
2.37%
Employees
142.00
Rev per Employee
$80.00k
Show more

Is Profound Medical Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Profound Medical Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Profound Medical Corp forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Profound Medical Corp forecast:

Buy
83%
Hold
17%

Financial data from Profound Medical Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
12 12
64% 64%
100%
- Direct Costs 3.84 3.84
37% 37%
32%
8.02 8.02
81% 81%
68%
- Selling and Administrative Expenses 27 27
38% 38%
224%
- Research and Development Expense 18 18
23% 23%
150%
-36 -36
27% 27%
-300%
- Depreciation and Amortization 0.79 0.79
32% 32%
7%
EBIT (Operating Income) EBIT -36 -36
24% 24%
-307%
Net Profit -32 -32
14% 14%
-269%

In millions USD.

Don't miss a Thing! We will send you all news about Profound Medical Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Profound Medical Corp Stock News

Neutral
GlobeNewsWire
about one month ago
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the M...
Neutral
Seeking Alpha
about 2 months ago
Profound Medical Corporation (NASDAQ:PROF ) Q1 2025 - Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Stephen Kilmer - Head IR Rashed Dewan - CFO Dr. Mathieu Burtnyk - COO Tom Tamberrino - Chief Commercial Officer Arun Menawat - CEO Conference Call Participants Ben Haynor - Lake Street Capital Markets John McAuley - Stifel Michael Freeman - Raymond James Scott McAuley - Par...
Neutral
GlobeNewsWire
about 2 months ago
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2025 Bloom Burton & Co. Healthcare Investor C...
More Profound Medical Corp News

Company Profile

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. Its platforms offer clinicians and patients incision-free alternatives to current standards of care which could include traditional surgery or radiation therapy. Its products include TULSA-PRO and Sonalleve. The company was founded in 2008 and is headquartered in Mississauga, CA.

Head office Canada
CEO Arun Menawat
Employees 142
Founded 2008
Website profoundmedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today